Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 2063152)

Published in Br J Cancer on October 01, 1998


R Hoffmann1, I Müller, K Neuber, S Lassmann, J Buer, M Probst, K Oevermann, A Franzke, H Kirchner, A Ganser, J Atzpodien

Author Affiliations

1: Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.

Articles cited by this

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36

Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol (1992) 2.26

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep (1984) 1.51

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol (1997) 0.98

Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol (1997) 0.98

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer (1995) 0.95

Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer (1992) 0.90

Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer (1996) 0.83

Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. Br J Haematol (1997) 0.81

Articles by these authors

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97

Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87

Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55

Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26

Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19

The immunobiology of zinc. Immunol Today (1997) 2.93

Effective protection against Listeria monocytogenes and delayed-type hypersensitivity to listerial antigens depend on cooperation between specific L3T4+ and Lyt 2+ T cells. Infect Immun (1985) 2.70

High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48

Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46

Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40

Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science (1996) 2.35

Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology (2001) 2.34

Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13

Value of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. Infection (2014) 2.09

Herpesvirus saimiri DNA in a lymphoid cell line established by in vitro transformation. J Virol (1984) 2.09

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07

Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06

TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05

Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79

Modifications of CD8+ T cell function during in vivo memory or tolerance induction. Immunity (1998) 1.76

Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74

Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin Immunol (1999) 1.71

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69

Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67

Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun (1996) 1.67

Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66

Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J (2003) 1.64

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62

Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62

Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60

CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer (2002) 1.59

Associations of peak shifts in age--prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg (2001) 1.58

Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand (2011) 1.58

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57

Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55

Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells. Cancer Biother Radiopharm (2002) 1.55

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55

Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53

SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50

Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47

Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46

Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45

Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity (1997) 1.44

The presence of Herpesvirus Saimiri genomes in virus-transformed cells. Int J Cancer (1977) 1.43

Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet (1994) 1.43

Impact of low copy repeats on the generation of balanced and unbalanced chromosomal aberrations in mental retardation. Cytogenet Genome Res (2006) 1.42

Clinical improvement in psoriasis during dithranol/UVB therapy does not correspond with a decrease in elevated serum soluble ICAM-1 levels. Arch Dermatol Res (1993) 1.42

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42

Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro. Pediatr Hematol Oncol (1992) 1.41

Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41

Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm (1991) 1.41

Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia (2003) 1.41

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood (1997) 1.40

Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet (1993) 1.40

[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40

Some Considerations of Vertigo based on Experience. Proc R Soc Med (1928) 1.39

Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38

Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol (1998) 1.37

Calendar life span versus budding life span of Saccharomyces cerevisiae. Mech Ageing Dev (1980) 1.36

The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35

The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34

Kinetics of the Zn 2+ - stimulation of human peripheral lmphocytes in vitro. Proc Soc Exp Biol Med (1971) 1.34

Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol (2013) 1.33

Haemoparasites of equines: impact on international trade of horses. Rev Sci Tech (1990) 1.31

Parental age and the life-span of zygotes of Saccharomyces cerevisiae. Antonie Van Leeuwenhoek (1985) 1.31

Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill (2011) 1.30

A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand (2011) 1.29

Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28

Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun (2001) 1.28

Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med (1998) 1.28

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28

Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol (1983) 1.27

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27

Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26

Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol (1981) 1.25

Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol (2004) 1.25

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer (2009) 1.25

Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity. Eur J Immunol (1991) 1.25

GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med (2009) 1.25

Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res (1999) 1.24

In vitro mitogenic stimulation of murine spleen cells by herpes simplex virus. J Immunol (1978) 1.24

Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell. J Immunol (1984) 1.24